Company record · RNAZ · Pharmaceutical Preparations
Transcode Therapeutics, Inc.
Transcode Therapeutics, Inc.'s interim chief financial officer on the record is John Tattory, effective September 9, 2026, per the filing record.
The record holds 1 verified CFO change for Transcode Therapeutics, Inc. from Form 8-K filings, filed September 11, 2026 and its 10-K filed April 15, 2026, where no CFO signature could be established.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled (interim) |
|---|---|
| Officer | John Tattory |
| Title as printed | Interim Chief Financial Officer, principal financial officer and principal accounting officer |
| Basis | Latest move: interim, 8-K filed September 11, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-09-11Interim
TransCode Therapeutics, Inc. names John Tattory interim CFOeffective September 9, 2026 · 8-K filed September 11, 2026 · sec.gov, Item 5.02
2026-04-1510-K signature
CFO signature not established from the annual report
10-K filed April 15, 2026 · sec.gov
Company
| Ticker | RNAZ |
|---|---|
| SEC CIK | 0001829635 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | From the 10-K filed 2026-04-15: no conformed signature "/s/ Thomas A. Fitzgerald, MBA" in the signature section. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.